Metaescaline: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 30: | Line 30: | ||
[[Category:Phenethylamines]] | [[Category:Phenethylamines]] | ||
{{Psychoactive-stub}} | {{Psychoactive-stub}} | ||
<gallery> | |||
File:Metaescaline.svg|Metaescaline | |||
</gallery> | |||
Latest revision as of 04:59, 3 March 2025
Metaescaline (also known as 3,4,5-trimethoxy-4-ethylphenethylamine) is a psychedelic and hallucinogenic drug, which is structurally related to mescaline. It was first synthesized by Alexander Shulgin, a renowned chemist and psychopharmacologist.
History[edit]
Metaescaline was first synthesized and documented by Alexander Shulgin in his book PiHKAL (Phenethylamines I Have Known And Loved). Shulgin's research has contributed significantly to the understanding of the pharmacology of phenethylamine derivatives.
Pharmacology[edit]
Metaescaline is a phenethylamine, but its pharmacological action is not fully understood. It is believed to act as a serotonin receptor agonist, similar to other psychedelic drugs. This means it binds to and activates certain serotonin receptors in the brain, which can lead to altered perceptions and hallucinations.
Effects[edit]
The effects of metaescaline can vary greatly depending on the dose, individual physiology, and set and setting. Common effects reported include visual hallucinations, enhanced colors, altered thought processes, and a sense of euphoria. Some users also report experiencing negative effects such as nausea, anxiety, and confusion.
Legal Status[edit]
The legal status of metaescaline varies by country. In the United States, it is not specifically listed as a controlled substance, but it could potentially be considered an analog of mescaline, which is a Schedule I drug under the Controlled Substances Act.
See Also[edit]

This article is a psychoactive drug-related stub. You can help WikiMD by expanding it!
-
Metaescaline